Deep in the Colombian Amazon region of Serrania De La Lindosa, a roughly 12-mile stretch of rock is covered in a vast ...

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

Wedbush restated their outperform rating on shares of Scholar Rock (NASDAQ:SRRK – Free Report) in a research note published on Wednesday,RTT News reports. They currently have a $47.00 target price on ...

Scholar Rock is asking the U.S. Food and Drug Administration to approve apitegromab for people with spinal muscular atrophy.

CAMBRIDGE, MA—Ho Junlin, General Counsel of Scholar Rock Holding Corp (NASDAQ:SRRK), recently sold 9,039 shares of the company's common stock. The shares were sold at an average price of $44. ...

1 Day SRRK -1.75% DJIA 0.78% S&P 500 1.00% Health Care/Life Sciences 1527.34% ...

She transitioned into reporting while working for Rock the Vote, Future Majority and Wiretap Magazine, covering the Millennial Generation's perspective during the presidential elections.

CAMBRIDGE, Mass., January 17, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

In recent trading, shares of Scholar Rock Holding Corp (Symbol: SRRK) have crossed above the average analyst 12-month target price of $44.00, changing hands for $44.32/share. When a stock reaches ...